Hainan Meikangda Pharmaceutical

Hainan Meikangda Pharmaceutical Co., Ltd. is an integrated pharmaceutical company established in 2008, specializing in the research, development, production, and commercialization of advanced drug delivery systems. Following a major equity restructuring in 2021, the company has established specialized research laboratories in Chengdu and Shanghai, focusing on complex formulations such as inhalation, nasal, liposomal, and sustained-release drug delivery systems. Its therapeutic focus primarily covers respiratory and central nervous system (CNS) diseases, aiming to achieve import substitution for complex generics and innovative drugs in China. The company is currently constructing a large-scale vertical integration manufacturing base under its subsidiary Jiangsu Demai Pharmaceutical in Haimen, Jiangsu, to support its transition from pilot-scale to commercial production.